Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has obtained access to rights for an antibody program from WILEX, originally obtained from UCB in 2009, for non-oncology indications.
Subscribe to our email newsletter
Under the deal, UCB gains rights to develop the antibodies from the program for non-oncology indications such as immunology/inflammation, while WILEX holds rights to develop antibodies for oncology indications.
UCB new medicine executive vice president and chairman Ismail Kola said, "Leveraging UCB’s scientific expertise in immunology, we will now take the program forward and explore it further in immunology indications where there are severe unmet needs".
WILEX will reimburse an undisclosed amount for the costs associated with the development to date and will also earn future, undisclosed development, regulatory and commercial milestone payments and royalties.
The data regarding the program will continue to be shared between both the companies and WILEX will have access to relevant data from non-oncology indications for assistance in oncology.
WILEX executive management board chairman Olaf Wilhelm said, "An identified lead antibody and generated data attracted UCB to purchase the rights to indications outside oncology at such an early stage which is not only a validation of our capabilities but also proof of our excellent partnership with UCB."